Clinical Trials Browser

OTHER_GOV × Interventional × tislelizumab × Clear all

NCT07469306 2026-03-13

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

130 enrolled

Gastrointestinal

Locally Advanced Rectal Cancer

NCT07331428 2026-01-09

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

Phase 2 Not yet recruiting

25 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07320105 2026-01-06

Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)

Phase 4 Recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06333769 2025-08-15

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

Phase 2 Completed

38 enrolled

Gastrointestinal

Mid-low Rectal Cancer

NCT06793917 2025-07-20

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 3 Recruiting

269 enrolled

Gastrointestinal

Stomach Neoplasms

NCT07046221 2025-07-20

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

Phase 2 Not yet recruiting

60 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT06692270 2025-02-28

Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma

Phase 2 Not yet recruiting

20 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT05319639 2025-02-27

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Phase 1/2 Recruiting

51 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06793228 2025-01-27

Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia

Phase 2 Not yet recruiting

250 enrolled

Thoracic

SCLC, Extensive Stage

NCT06554028 2024-08-14

Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer

Phase 2 Not yet recruiting

46 enrolled

Head & Neck

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT05628610 2024-08-13

Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer

Phase 2 Not yet recruiting

130 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT04924413 2024-07-03

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Phase 2 Terminated

9 enrolled

Dermatologic

Melanoma

NCT05878028 2024-05-23

L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC

Phase 2 Recruiting

33 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06218888 2024-01-23

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

Phase 2 Not yet recruiting

17 enrolled

Gastrointestinal

Colonic Neoplasms

NCT06197438 2024-01-09

Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

Phase 2 Unknown

36 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05751265 2023-06-22

Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer

Phase 2 Unknown

39 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05479240 2023-06-18

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

94 enrolled

Immunotherapy

NCT05897138 2023-06-13

A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses

Phase 2 Not yet recruiting

30 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05799443 2023-04-05

Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer

Phase 2 Unknown

23 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05407519 2023-03-22

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05545124 2022-09-19

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Phase 2 Unknown

32 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05314101 2022-08-23

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Phase 2 Unknown

25 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05192681 2022-01-14

Tislelizumab as Cross-line Treatment for Advanced NSCLC

Phase 2 Unknown

35 enrolled

Thoracic

Advanced Non-small-cell Lung Cancer